“…Therefore, patient-reported HRQOL and participation are now widely recognized as important outcome measures when assessing treatment efficacy in RA, allowing for better understanding of the correlation between different aspects of disease activity and its broad burden on patients 5,6 . Patient-reported outcomes (PRO), including global assessment of disease activity, pain, physical function, measures of HRQOL, and fatigue, are commonly used to assess efficacy in RA randomized controlled trials 7 , and their inclusion in clinical practice has become increasingly important 8,9 . In addition, assessment of participation in RA, e.g., productivity, as well as engagement in family/social and leisure activities, offers value from both individual and societal perspectives 5,10,11 .…”